# What are epitalon, MOTS-c, thymosin alpha-1 and SS-31?

> Epitalon, MOTS-c, thymosin alpha-1 and SS-31 (elamipretide) are unrelated peptides; none has been shown to slow aging in people, and only elamipretide is FDA-approved, for a rare inherited disease. No published study has given MOTS-c to people, epitalon’s human studies are few and small, and two large thymosin alpha-1 trials, in sepsis and pancreatitis, missed their main goals.

The journal is published by Rovere, a telehealth service that sells some of the treatments discussed here. Articles are general information, not medical advice. Only a licensed clinician can say whether a treatment is right for you.

- Topic: Compounds
- Web page: https://roverehealth.com/journal/longevity-peptides

## Key points

- Elamipretide (SS-31) is FDA-approved, unlike epitalon, MOTS-c and thymosin alpha-1. Its 2025 accelerated approval, to improve muscle strength in Barth syndrome, a rare inherited disease, may depend on a confirmatory trial, and its label warns of serious allergic reactions.
- Epitalon is a lab-made peptide of four amino acids, modeled on an extract of cattle pineal glands. A 2026 FDA review found no clinical data on its safety; most studies of its effects came from one Russian group.
- MOTS-c is a 16-amino-acid peptide encoded in the DNA of mitochondria, the energy-producing parts of cells, and described in 2015. The FDA found no published study that had given it to people, and the World Anti-Doping Agency bans it.
- Thymosin alpha-1 is approved in some countries, mainly for chronic hepatitis B, but not in the US. A 2025 double-blind trial of 1,106 adults with sepsis found no difference in deaths within 28 days compared with placebo.
- FDA staff opposed listing epitalon, MOTS-c or thymosin alpha-1 for compounding. Under a nonbinding draft’s conditions, HHS says it does not intend to take enforcement action against pharmacies compounding epitalon or MOTS-c injections under the skin or into a muscle.

## At a glance

| Compound | Kind | How it is taken | FDA status | Research in people |
| --- | --- | --- | --- | --- |
| Epitalon (also: Epithalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly) | Lab-made peptide of four amino acids, modeled on a cattle pineal extract | Under the tongue, or injection next to the eye (in studies); injection, capsule or mouth spray (as sold) | Not FDA-approved; FDA staff opposed adding it to the 503A bulks list; in a nonbinding 2026 draft, HHS says it does not intend to take enforcement action against 503A compounding of epitalon acetate for under-the-skin or muscle injection, dispensed in intermittent courses, under its conditions. (checked 2026-11-14) | Small trials in people. A 2021 randomized, placebo-controlled study of 40 women, mostly night-shift workers, found a melatonin by-product rose with an under-the-tongue spray but not with placebo; it did not measure sleep. No randomized trial has tested whether epitalon slows aging, the use clinics market it for. |
| MOTS-c (also: Mitochondrial open reading frame of the 12S rRNA-c, MOTs-C) | Peptide of 16 amino acids encoded in mitochondrial DNA | Injection, including into a vein (as sold; no published study in people) | Not FDA-approved; FDA staff opposed adding it to the 503A bulks list; in a nonbinding 2026 draft, HHS says it does not intend to take enforcement action against 503A compounding of MOTS-c acetate for under-the-skin or muscle injection under its conditions. (checked 2026-11-14) | Lab and animal studies only. No published study has given MOTS-c to people; studies in people have only measured the MOTS-c the body makes. An 88-person safety trial of a modified version, CB4211, ended in 2021 with no results in its registry entry or PubMed. |
| Thymosin alpha-1 (also: Thymalfasin, Ta1) | Immune-acting peptide of 28 amino acids, made by the body (approved in some countries outside the US) | Injection under the skin (in trials); injection or nasal spray (as sold) | Not FDA-approved for any use; in December 2024 FDA advisers voted 17 to 4 against adding each form to the 503A bulks list of extra compounding ingredients, and the FDA had not decided by November 13, 2026. (checked 2026-11-13) | Large trials in people. Two large double-blind trials, in 1,106 adults with sepsis (2025) and 508 with predicted severe acute necrotizing pancreatitis (2022), found no benefit on their main outcomes. Both enrolled critically ill hospital patients, not the people it is marketed to online for immune support. |
| Elamipretide (also: SS-31, MTP-131, Elamipretide hydrochloride) | Peptide of four amino acids that targets mitochondria (FDA-approved prescription drug) | Injection under the skin | FDA-approved on September 19, 2025, under accelerated approval, to improve muscle strength in Barth syndrome in patients weighing at least 30 kilograms (66 pounds); the FDA requires a trial to confirm the benefit. (checked 2026-11-13) | Large trials in people. The largest published randomized trials, in 300 adults treated for heart attack (2016) and 218 with mitochondrial muscle disease (2023), found no clear benefit. Its Barth approval rests on a 12-patient trial; no trial has tested whether it slows aging or tested a compounded version. |

## What they are

Epitalon, MOTS-c, thymosin alpha-1 and SS-31 (elamipretide) are unrelated peptides, short chains of amino acids, the building blocks of proteins. Only elamipretide is FDA-approved, and only to improve muscle strength in Barth syndrome, a rare inherited disease of mitochondria, the energy-producing parts of cells. FDA documents show that each has been promoted or proposed for aging, or for immunity in older people. [1, 2, 3, 4, 5, 6]

Epitalon is a lab-made peptide of four amino acids, modeled on epithalamin, an extract of cattle pineal glands. The pineal gland, in the brain, makes melatonin, a hormone involved in sleep. Most studies of epitalon’s effects came from one group, led by Vladimir Khavinson in St Petersburg, Russia, the FDA’s 2026 review found. [3, 7]

The genetic code for MOTS-c, a 16-amino-acid peptide, sits in the DNA of mitochondria, not in the cell’s nucleus. Researchers at the University of Southern California described it in 2015 and found it in the blood of people and rodents. [8, 4]

The body makes thymosin alpha-1, a 28-amino-acid peptide first isolated in 1977 from calf thymus, an immune gland. A lab-made version is called thymalfasin. An FDA review lists approvals abroad, mainly for chronic hepatitis B and, in Italy, as an add-on to flu vaccination for people with weakened immune systems. [9, 5]

Like epitalon, elamipretide is a lab-made chain of four amino acids. It belongs to the Szeto-Schiller family of peptides, the SS in SS-31, which collect in the inner membrane of mitochondria. There it binds cardiolipin, a fat molecule found only in that membrane. [2, 10]

## How they work

How epitalon acts in the body has not been established. Khavinson’s group reported in 2003 that it switched on telomerase in human fetal cells grown in a dish. Telomerase is an enzyme that lengthens telomeres, protective chromosome caps that shorten each time a cell divides. In one study in older monkeys, epitalon raised evening melatonin, but in a lab test it did not make rat pineal glands release more. [7, 3]

In a 2015 study in mice, MOTS-c appeared to act mainly on muscle and switched on AMPK, an enzyme that helps cells manage energy. Mice on a high-fat diet given it gained less weight and stayed more sensitive to insulin than untreated mice. All such studies have been in rodents, the FDA notes, and the molecule MOTS-c acts on is unknown. [8, 4]

In lab and animal studies, thymosin alpha-1 activates toll-like receptors, sensors that immune cells use to detect infection. Most of those studies used doses far above those in human trials, so their relevance is unclear, the FDA says. [5]

Barth syndrome is caused by faults in a gene called TAZ, which leave cardiolipin abnormal. Elamipretide’s FDA-approved label says the drug improves the structure and function of mitochondria. [11, 2]

## How they are taken

Routes in published studies in people, and forms the FDA found sold or compounded. [3, 4, 12, 5, 2, 13, 14, 6]

| Peptide | In published studies in people | What the FDA found sold or compounded |
| --- | --- | --- |
| Epitalon | Under the tongue; injections next to the eye | Injections, capsules and an oral spray, some labeled for research use only |
| MOTS-c | None published; a modified version, CB4211, was injected under the skin in an unpublished trial | Injections, alone or in mixtures, including drips into a vein |
| Thymosin alpha-1 | Injection under the skin | Injections and nasal sprays |
| Elamipretide | Injection under the skin; single infusions into a vein in some trials | The approved injection; also SS-31 sold online for research use only |

## What the research in people shows

Reviewing epitalon for one proposed use, insomnia, the FDA found three published studies that gave it to people, all by Khavinson or his co-authors. Two, both from 2021, gave it under the tongue to night-shift workers. The third, from 2002, gave injections next to the eye to people with retinitis pigmentosa, an inherited eye disease. [3]

One of the night-shift studies was randomized and placebo-controlled. Forty women aged 40 to 50 with low levels of a melatonin by-product got an epitalon or placebo spray under the tongue for 20 days. The by-product rose with epitalon but not with placebo. The study was small and short and did not measure sleep or say who knew which spray each woman got, the FDA noted. [3]

No published study has given MOTS-c to people, the FDA found in 2026; published human studies have measured only the MOTS-c the body makes. A 12-week placebo-controlled trial of MOTS-c in adults with prediabetes and excess weight, planned to enroll 120, began in China in February 2026. [4, 15, 16]

A modified version, CB4211, was tested in a randomized, placebo-controlled safety trial of 88 adults, some with fatty liver disease, that ended in April 2021. As of November 14, 2026, neither its registry entry nor PubMed, an index of medical research, lists results. A draft policy from the Department of Health and Human Services (HHS) says an unnamed randomized, placebo-controlled trial of a modified version of MOTS-c reported no serious adverse events. CB4211’s sponsor, CohBar, licensed the rights to MOTS-c, and the 2015 discovery paper’s senior author owned CohBar shares. [12, 46, 17, 8]

The FDA’s 2024 review of 12 uses of thymosin alpha-1, including hepatitis B, sepsis and COVID-19, found a lack of evidence for every one, partly because the studies were small or flawed. Two large double-blind trials, in which neither patients nor doctors knew who got the drug, found no benefit on their main outcomes. [5, 18, 19]

Two large double-blind trials of thymosin alpha-1. [18, 19]

| Trial | Who took part | Design | Main result |
| --- | --- | --- | --- |
| TESTS, 2025 | 1,106 adults with sepsis, a life-threatening reaction to infection, at 22 hospitals in China | Double-blind, placebo-controlled, up to 7 days of injections | No difference in deaths within 28 days |
| Ke and colleagues, 2022 | 508 people in China with predicted severe acute necrotizing pancreatitis, a sudden inflammation in which pancreatic tissue dies | Double-blind, placebo-controlled | No reduction in infection of the damaged pancreas |

A 2026 Cochrane review, which pools all eligible trials under fixed rules, covered 10 randomized trials in 1,349 people with chronic hepatitis B. It found results favoring thymosin alpha-1, but rated the evidence too uncertain to say it reduces deaths. A 2025 review of 11 sepsis trials found fewer deaths overall, but not among better-designed or multicenter trials. [20, 21]

The evidence in elamipretide’s label comes from 12 males with Barth syndrome. In a double-blind crossover trial, each took elamipretide and placebo for 12 weeks apiece, in random order. The drug did no better than placebo on walking distance or fatigue, the main measures. The strength of the thigh muscles that straighten the knee (knee extensor strength) rose only in the open-label extension that followed, where everyone knew they were on the drug. Eight took it for more than three years. [2, 11]

The trial’s authors reported that walking distance and fatigue also improved during the extension. In 2025 the FDA judged those gains unreliable. The walking test depends on effort, patients knew they were on the drug, and both measures had also improved on placebo during the double-blind phase. [22, 23]

Stealth BioTherapeutics, the approval holder, sponsored 20 of 22 elamipretide studies on ClinicalTrials.gov as of November 13, 2026. Its larger published randomized trials in other conditions missed their main goals. They enrolled 300 adults treated for a first heart attack (2016), 218 people with a genetic mitochondrial muscle disease (2023) and 176 with dry macular degeneration, an eye disease (2024). In 39 healthy people aged 60 to 85, one infusion brought only a borderline, short-lived rise in a muscle energy measure. [30, 24, 13, 25, 26, 27, 14]

## Side effects and risks

For all three unapproved peptides, the FDA raises immunogenicity: the chance the immune system reacts against the peptide. Clumps and manufacturing impurities raise that risk, which may be higher with injections under the skin. Reactions range from symptom-free antibodies to life-threatening ones. Because the body makes its own MOTS-c and thymosin alpha-1, antibodies could also block the body’s own. [28, 3, 4, 5]

The FDA warned that products sold under informal names like epitalon and MOTS-c can contain a different form of the peptide or even a different substance from the one prescribed. The agency’s adverse event database held no reports on either, though compounding pharmacies generally do not report adverse events to it. [3, 4]

The FDA found no clinical data on epitalon’s safety and no data on how people absorb or clear it. FDA staff raised a cancer question: epitalon switches on telomerase in lab studies, and longer telomeres are generally linked to higher cancer risk. Researchers including Khavinson reported fewer tumors in female mice given epitalon, but the FDA judged those studies too limited and found no two-year cancer study in animals. A 2025 lab study found epitalon lengthened telomeres in human breast cancer cells as well as normal cells. [3, 29]

For MOTS-c, the FDA found no human safety data and no animal toxicity studies. With its target unknown, it is hard to predict which organs MOTS-c might affect, the FDA says. [4]

The most common side effects in thymosin alpha-1 trials were irritation, redness or discomfort where it was injected. TESTS found no difference in safety outcomes. In its planned look at people under 60, though, more died on thymosin alpha-1 than on placebo. The authors said differences between the groups at the start may explain part of this. [5, 18]

Labels abroad rule out thymosin alpha-1 for children and in pregnancy or breastfeeding, and advise against it for transplant recipients and others whose immune systems are deliberately suppressed. They urge caution with allergies, other immune-acting drugs and autoimmune disease. After stem cell transplants, the FDA said, it could trigger or worsen graft-versus-host disease, an attack by transplanted immune cells on the body, or cause graft failure. In one small study, 1 of 6 people given it after a half-matched stem cell transplant died of an immune attack on their red blood cells. That person had also received donor immune cells; the FDA said it is unclear whether the peptide contributed. [5]

Elamipretide’s label warns of allergic reactions, including serious ones that needed emergency treatment, starting minutes to months after the first dose. Anyone who has had a serious allergic reaction to it or its ingredients must not use it. Its preservative, benzyl alcohol, has caused fatal reactions in premature and low-birth-weight newborns given it into a vein; elamipretide is not approved for newborns. [2]

In the Barth trial, all 12 patients had injection-site reactions on elamipretide, against 8 of 12 on placebo. Symptom-free rises in eosinophils, a type of white blood cell, were common with use of 30 days or more. The label calls for a lower dose in adults with severe kidney impairment and says the drug has not been studied in people on dialysis. [2]

## FDA status

On September 19, 2025, the FDA granted elamipretide accelerated approval to improve muscle strength in people with Barth syndrome who weigh at least 30 kilograms (66 pounds). Accelerated approval rests on a measure the FDA judges reasonably likely to predict a real benefit, here knee extensor strength. Continued approval may depend on a randomized, placebo-controlled trial that began in July 2026 and is due to finish in 2029. [1, 30, 2, 31]

The approved ingredient is elamipretide hydrochloride, a salt form: the peptide combined with hydrochloric acid. Because it is part of an FDA-approved drug, state-licensed pharmacies may compound with it, subject to the law’s other conditions. Other salt forms of a peptide count as different ingredients. The law also bars pharmacies from compounding what are essentially copies of a commercially available drug, such as the approved product, regularly or in inordinate amounts. Compounded elamipretide is not FDA-approved. [30, 2, 32, 3, 33, 34]

SS-31 sold online is not the approved drug either. FDA warning letters in August 2026 told online sellers that their SS-31, despite research-use-only labels, was an unapproved new drug marketed with claims about mitochondria and aging. Injected products bypass some of the body’s defenses against toxins and germs, the FDA warned. [6, 35]

Thymosin alpha-1, epitalon and MOTS-c are not FDA-approved. None has an official quality standard (a USP monograph) or is part of an approved drug. So federal law lets a state-licensed pharmacy (compounding under section 503A) use them only if the FDA adds them to the 503A bulks list, its list of extra ingredients for compounding. [5, 3, 4, 32]

On October 30, 2026, HHS, the FDA’s parent department, announced its draft policy on six peptides. They include epitalon and MOTS-c, but not thymosin alpha-1 or SS-31. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding them under section 503A when all ten of its conditions are met. For these two, it covers only the acetate salt form of each, injected under the skin or into a muscle, and epitalon only when dispensed in intermittent courses. [34, 46]

Its conditions include one active ingredient per product, so no blends. The draft is not binding, is not an approval and adds nothing to the 503A bulks list. [46, 34]

Where the three unapproved peptides stand in the FDA’s compounding review, as of November 14, 2026. [5, 36, 3, 4, 37, 38, 46]

| Peptide | FDA staff review | Advisory committee |
| --- | --- | --- |
| Thymosin alpha-1 | Advised against listing, 2024 | Voted 17 to 4 against listing each form, December 2024 |
| Epitalon | Advised against listing, May 2026 | Voted in favor of listing, July 2026, according to HHS; the FDA has not posted the results |
| MOTS-c | Advised against listing, May 2026 | Voted in favor of listing both forms, July 2026, according to HHS; the FDA has not posted the results |

All three were once in Category 2, substances that “may present significant safety risks”. Their nominations, which had confused the plain peptides with their acetate salts, were withdrawn, and the FDA reviewed them anyway. None is now in Category 1, the group the FDA’s own interim policy does not act against. [28, 3, 4, 5, 39, 32]

## Rules in sport

The World Anti-Doping Agency’s 2026 Prohibited List bans MOTS-c at all times. It names thymosin beta-4, a different peptide, but not thymosin alpha-1, epitalon or elamipretide. A catch-all section also bans substances that no government health regulator has approved for human use, and from 2027 it names peptides among its examples. [40, 41]

## What isn’t known

- Whether epitalon, MOTS-c or elamipretide slows aging in people. No randomized trial has tested it.
- Whether epitalon raises cancer risk over years of use.
- Whether thymosin alpha-1 adds benefit to today’s standard care for any disease the FDA reviewed.
- Whether the knee extensor strength gains mean people with Barth syndrome function better.
- Whether long-term elamipretide use affects cancer risk. No animal cancer studies were done before approval; the FDA required them, including a two-year rat study due to finish in 2029.
- Whether elamipretide changes levels of metformin, a diabetes drug. In lab tests it blocks a transporter that carries metformin; an FDA-required study is due in 2027.
- What three finished randomized trials of elamipretide found: in 308 and 46 people with heart failure (both ended 2017) and 102 with mitochondrial disease (ended 2024). None lists results in its registry entry or on PubMed.
- Whether the FDA will add epitalon or MOTS-c to the 503A bulks list. HHS’s draft would apply until a final rule decides each one, unless HHS revisits it, and gives no date for that rule.

Sources for the list above: [3, 4, 24, 5, 1, 31, 2, 42, 43, 44, 45, 46]

## Questions to ask a clinician

- Has this peptide been tested in people with my condition, and in what kind of study?
- Is this the FDA-approved product, a compounded drug or a product labeled for research use only?
- If it is compounded, which law, FDA list or HHS policy is the pharmacy relying on, and does it cover this exact salt form and route?
- Could it affect an autoimmune disease, a transplant, a pregnancy or my other medicines?

## Sources

1. FDA. FDA grants accelerated approval to first treatment for Barth syndrome (news release). 2025. Regulator. Checked 2026-11-13. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome
2. National Library of Medicine, DailyMed. Elamipretide injection: FDA-approved prescribing information (September 2025). 2025. Regulator. Checked 2026-11-13. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75
3. FDA. Briefing document: evaluation of epitalon-related bulk drug substances (epitalon free base and epitalon acetate), Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/media/193345/download
4. FDA. Briefing document: evaluation of MOTS-c-related bulk drug substances (MOTS-c free base and MOTS-c acetate), Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/media/193347/download
5. FDA. Briefing document: evaluation of thymosin alpha-1 (Ta1)-related bulk drug substances (Ta1 free base and Ta1 acetate), Pharmacy Compounding Advisory Committee meeting, December 4, 2024. 2024. Regulator. Checked 2026-11-13. https://www.fda.gov/media/183820/download
6. FDA. Warning letter 734884 on SS-31 (elamipretide) and other peptides sold online for research use. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026
7. Khavinson VKh et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003. Lab study. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/12937682/
8. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. Animal study. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/25738459/
9. Goldstein AL et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A. 1977. Lab study. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/265536/
10. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014. Reference. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/24117165/
11. Reid Thompson W et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021. Trial in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/33077895/
12. ClinicalTrials.gov. NCT03998514: A phase 1a/1b study of CB4211 in healthy non-obese subjects and subjects with nonalcoholic fatty liver disease. 2021. Trial in people. Checked 2026-11-14. https://clinicaltrials.gov/study/NCT03998514
13. Gibson CM et al. EMBRACE STEMI study: a phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016. Trial in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/26586786/
14. Roshanravan B et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021. Trial in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/34264994/
15. Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. Mostly mouse experiments, with an exercise study in 10 men. Observational study in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/33473109/
16. ClinicalTrials.gov. NCT07505745: MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight/obesity (MOTS-MET). 2026. Trial in people. Checked 2026-11-13. https://clinicaltrials.gov/study/NCT07505745
17. Miller B et al. Mitochondria-derived peptides in aging and healthspan. J Clin Invest. 2022. Reference. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/35499074/
18. Wu J et al. The efficacy and safety of thymosin alpha 1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025. Trial in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/39814420/
19. Ke L et al. Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial. Intensive Care Med. 2022. Trial in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/35713670/
20. Naing C et al. Thymosin-alpha1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026. Systematic review. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/42713852/
21. Gu B et al. Efficacy of thymosin alpha1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2025. Systematic review. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/40969554/
22. Thompson WR et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024. Trial in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/38602181/
23. FDA. Complete response letter for NDA 215244, elamipretide injection, May 15, 2025 (Drugs@FDA, other action letters). 2025. Regulator. Checked 2026-11-13. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000OtherActionLtrs.pdf
24. ClinicalTrials.gov. Search results: studies with elamipretide as an intervention (22 records as of November 13, 2026). 2026. Reference. Checked 2026-11-13. https://clinicaltrials.gov/search?intr=elamipretide
25. ClinicalTrials.gov. NCT01572909: Evaluation of myocardial effects of MTP-131 for reducing reperfusion injury in patients with acute coronary events (EMBRACE STEMI). 2020. Trial in people. Checked 2026-11-13. https://clinicaltrials.gov/study/NCT01572909
26. Karaa A et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023. Trial in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/37268435/
27. Ehlers JP et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation. Ophthalmol Sci. 2024. Trial in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/39605874/
28. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (category 2 list, content current as of April 22, 2026). 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
29. Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. Corrected in 2025: figures 1 to 3 replaced. Lab study. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/40908429/
30. FDA. Drugs@FDA: NDA 215244, elamipretide hydrochloride injection. 2025. Regulator. Checked 2026-11-13. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215244
31. ClinicalTrials.gov. NCT07531251: Phase 3b/4 randomized, double-blind, placebo-controlled trial of elamipretide in patients with Barth syndrome (4TAZPower). 2026. Trial in people. Checked 2026-11-13. https://clinicaltrials.gov/study/NCT07531251
32. FDA. Bulk drug substances used in compounding under section 503A of the FD&C Act. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
33. FDA. Compounded drug products that are essentially copies of a commercially available drug product under section 503A of the Federal Food, Drug, and Cosmetic Act: guidance for industry. 2018. Regulator. Checked 2026-11-13. https://www.fda.gov/media/98973/download
34. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526. 2026. Regulator. Checked 2026-11-14. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
35. FDA. Warning letter 735127 on SS-31 and other peptides sold online for research use. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026
36. FDA. Final summary minutes of the Pharmacy Compounding Advisory Committee meeting, December 4, 2024. 2025. Regulator. Checked 2026-11-13. https://www.fda.gov/media/185642/download
37. FDA. Questions for the Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/media/193711/download
38. FDA. July 23-24, 2026: meeting of the Pharmacy Compounding Advisory Committee (meeting page). 2026. Regulator. Checked 2026-11-14. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
39. FDA. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (categories list, updated May 14, 2026). 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/media/94155/download
40. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. 2025. Regulator. Checked 2026-11-13. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
41. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. 2026. Regulator. Checked 2026-11-13. https://www.wada-ama.org/sites/default/files/2026-11/2027list_en_final_clean_4_nov_2026.pdf
42. FDA. Accelerated approval letter for NDA 215244, elamipretide injection, with postmarketing requirements. 2025. Regulator. Checked 2026-11-13. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215244Orig1s000ltr.pdf
43. ClinicalTrials.gov. NCT02914665: A phase 2 study to evaluate the cardiac and renal effects of short term treatment with elamipretide in patients hospitalized with congestion due to heart failure. 2020. Trial in people. Checked 2026-11-13. https://clinicaltrials.gov/study/NCT02914665
44. ClinicalTrials.gov. NCT02814097: A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the effects of 4 weeks treatment with subcutaneous elamipretide on left ventricular function in subjects with stable heart failure with preserved ejection fraction. 2017. Trial in people. Checked 2026-11-13. https://clinicaltrials.gov/study/NCT02814097
45. ClinicalTrials.gov. NCT05162768: Phase 3 trial of elamipretide in primary mitochondrial disease from nuclear DNA mutations (NuPower). 2025. Trial in people. Checked 2026-11-13. https://clinicaltrials.gov/study/NCT05162768
46. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (draft, revised November 6, 2026). 2026. Regulator. Checked 2026-11-14. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

## Related articles

- [Which peptides can a pharmacy compound?](https://roverehealth.com/journal/which-peptides-can-be-compounded.md): A pharmacy may compound with a raw peptide only if it meets an official quality standard, is in an FDA-approved drug, or is on an FDA list that names no peptide. Peptides that pass none of these, such as BPC-157, can rely at most on nonbinding FDA or HHS policies of not taking action, which are not approvals.
- [What are semax, selank, KPV and DSIP?](https://roverehealth.com/journal/semax-selank-kpv-and-dsip.md): Semax, selank, KPV and DSIP are short peptides promoted for focus, anxiety, inflammation and sleep; none is FDA-approved, no published study has given KPV to people, and DSIP’s small sleep studies conflicted. Semax and selank are registered in Russia, but FDA staff found too little evidence for any semax use they reviewed, and selank’s anxiety trials used no placebo.
- [What is NAD+, and what are NMN and NR?](https://roverehealth.com/journal/nad-plus.md): NAD+ is a coenzyme that every cell uses to turn food into energy, and NMN and NR are related molecules the body converts into it. No trial has shown that any of them slows aging in people, a 2026 trial linked NR to worse Parkinson symptoms than placebo, and NAD+ is not FDA-approved for any use.
- [What does “research use only” mean on a peptide?](https://roverehealth.com/journal/research-use-only-peptides.md): The label is a seller’s statement that a product is for laboratory research, not people: such a product has had no FDA review and is sold without a prescription. The FDA treats research-labeled peptides as unapproved drugs when they are sold for human use, and small lab studies of peptides bought online found wrong amounts and impurities.